Caspofungin Combination Therapy for Pediatric Aspergillosis
Author Information
Author(s): Cesaro Simone, Giacchino Mareva, Locatelli Franco, Spiller Monica, Buldini Barbara, Castellini Claudia, Caselli Desireè, Giraldi Eugenia, Tucci Fabio, Tridello Gloria, Rossi Mario Renato, Castagnola Elio
Primary Institution: Pediatric Hematology Oncology, Department of Pediatrics, University of Padua, Italy
Hypothesis
Is caspofungin-based combination therapy effective for treating invasive aspergillosis in pediatric hematological patients?
Conclusion
Caspofungin-based combination antifungal therapy is an effective treatment option for pediatric patients with invasive aspergillosis.
Supporting Evidence
- 53% of patients showed a favorable response to antifungal therapy.
- 100-day survival rate was 70%.
- Severe neutropenia was present in 78% of patients.
- 50% of patients were alive after a median follow-up of 0.7 years.
- Combination therapy was well tolerated with no severe renal or liver impairment.
Takeaway
This study shows that using a mix of antifungal medicines, including caspofungin, can help kids with serious fungal infections get better.
Methodology
Retrospective analysis of 40 children and adolescents treated with caspofungin-based combination therapy for invasive aspergillosis.
Potential Biases
Potential selection bias due to retrospective design.
Limitations
The study is retrospective and lacks a control group.
Participant Demographics
40 pediatric patients, median age 11.1 years, 21 males and 19 females.
Statistical Information
P-Value
p 0.003 for favorable response, p 0.04 for timing of IA diagnosis.
Confidence Interval
C.I. 55–84 for 100-day survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website